Esperion Therapeutics Inc. says FDA is on board with its plans to file bempedoic acid for LDL-lowering in high risk patients with its current Phase III program, eliminating lingering concerns that it would need cardiovascular outcomes data for submission and potentially giving them a differentiating claim for statin-intolerant patients.
Bempedoic acid (ETC-1002) is an oral inhibitor of ATP citrate lyase, an enzyme on the cholesterol biosynthesis pathway, that the...







